Members of the platelet-derived growth factor (PDGF) family are mitogens for cells of mesenchymal origin and have important functions during embryonic development, blood vessel maturation, fibrotic diseases and cancer. In contrast to the two classical PDGFs, the novel and less well-characterized members, PDGF-CC and PDGF-DD, are latent factors that need to be processed extracellularly by activating proteases, before they can mediate PDGF receptor activation. Here, we elucidate the structural requirements for urokinase plasminogen activator (uPA)-mediated activation of PDGF-DD, as well as the intricate interplay with uPA receptor (uPAR) signalling. Furthermore, we show that activated PDGF-DD, in comparison to latent, more potently transforms NIH/3T3 cells in vitro. Conversely, xenograft studies in nude mice demonstrate that cells expressing latent PDGF-DD are more tumorigenic than those expressing activated PDGF-DD. These findings imply that a fine-tuned proteolytic activation, in the local milieu, controls PDGF-DD bioavailability. Moreover, we suggest that proteolytic activation of PDGF-DD reveals a retention motif mediating interactions with pericellular components. Our proposed mechanism, where uPA not only generates active PDGF-DD, but also regulates its spatial distribution, provides novel insights into the biological function of PDGF-DD.
Introduction
For a long time it was thought that the platelet-derived growth factor (PDGF) family only consisted of PDGF-A and PDGF-B (Heldin and Westermark, 1999) . However, when PDGF-C and PDGF-D were discovered, new insights into this growth factor family were gained (Li et al., 2000; Bergsten et al., 2001; LaRochelle et al., 2001) . In addition to a conserved growth factor domain (GFD), shared by all four members, PDGF-C and PDGF-D contain an N-terminal CUB domain (Bork and Beckmann, 1993) within the full-length (fl) protein. So far, the functional role of the CUB domains in the novel PDGFs is not fully understood, but they have to be proteolytically removed before the factors can bind to and activate their cognate receptors, PDGFRa and PDGFRb. The need for extracellular activation implies an additional regulatory event that requires the presence of activating proteases.
Recently, we identified the serine protease tissueplasminogen activator (tPA) as a potent activator of latent dimeric PDGF-CC (Fredriksson et al., 2004 (Fredriksson et al., , 2005 and soon after, the closely related protease uPA was found to activate latent PDGF-DD (Ustach and Kim, 2005) . The findings that the novel PDGFs are substrates for plasminogen activators were surprising as the function of these proteases has long been considered to be to induce plasmin-mediated proteolysis and thereby control fibrinolysis, cell migration and tissue remodelling (Mondino and Blasi, 2004) .
The uPA/uPAR system has been extensively studied and its diverse functions generate a complexity strictly dependent on the microenvironment and presence of cofactors (Hoyer-Hansen et al., 1992; Simon et al., 2000; Liu et al., 2002; Ustach and Kim, 2005) . On account of its low zymogenic activity, single-chain (sc) uPA is usually referred to as a 53 kDa pro-enzyme. Upon secretion and subsequent cleavage, a conformational change leads to the formation of an A-chain containing an N-terminal EGF domain followed by a kringle domain, and a B-chain containing the C-terminal protease domain. This disulphide-linked two-chain high molecular weight (HMW) form can be further processed into a 33 kDa low molecular weight (LMW) form containing the protease domain and a shorter A-chain. The interaction between uPA and its glycosylphosphatidylinositol-anchored cell surface receptor uPA receptor (uPAR) is mainly retained within the EGF domain (Irigoyen et al., 1999) .
In this study, we investigate how the temporal and spatial presence of uPA and uPAR regulates PDGF-DD activity and function. We characterize the structural requirements for activation, identify uPAR as a regulator for PDGFRb signalling and furthermore, present evidence that removal of the CUB domain in latent PDGF-DD confers pericellular retention of the GFD, subsequently affecting tumorigenesis in vivo.
Taken together, our results emphasize the importance of a strictly regulated processing event governing the actions of PDGF-DD with direct implications in tumour development.
Results
The basic stretch of amino acids in the conserved putative cleavage site is important for PDGF-DD activation We have previously shown that PDGF-CC is processed in a conserved tribasic site by tPA (Fredriksson et al., 2004 (Fredriksson et al., , 2005 . In a sequence comparison between this identified region with the conserved basic stretch of amino acids in PDGF-D, processing may potentially also occur in the -R 254 KSK-site and not only in the -R 247 GR-site, recognized in the initial identification of uPA as a proteolytic activator of PDGF-DD (Ustach and Kim, 2005; Figure 1a ). To establish the importance of these basic amino acids for uPA-mediated activation, an alanine scan mutagenesis analysis was performed, where substitutions in the PDGF-D(fl) chain were made as depicted (Figure 1b) . The results showed that R 249 was necessary for cleavage to occur, and in addition, provided evidence for the functional importance of the conserved -R 254 KSK-site. However, given the limited alterations in cleavage efficacy after individual amino acid substitutions in the -R 254 KSK-site, these four residues are supposedly critical structural determinants that are not located directly in the cleavage site recognized by uPA. Supportive evidence was further provided in a tyrosine phosphorylation assay, where induction of PDGFRb activation was analysed ( Figure 1c) . Again, R 249 as well as the conserved -R 254 KSK-site were shown to be necessary for uPAmediated activation of PDGF-DD.
PDGF-DD interacts directly with uPA
To determine if PDGF-DD directly interacts with uPA, Ni-NTA-beads coated with PDGF-DD(fl) were incubated with uPA and bound proteins were analysed by immunoblotting. The results showed that scuPA could specifically bind PDGF-DD(fl) (Figure 2a) . Next, separate domain-domain interactions were studied in an enzyme-linked immunosorbent assay (ELISA) (Figure 2b ). The analysis identified interactions between the PDGF-DD(GFD) and HMWuPA as well as LMWuPA, whereas PDGF-D(CUB) alone displayed limited uPA-binding capacity.
PDGF-DD activation by uPA can be modulated by the presence of uPAR The structural requirements for recognition of latent PDGF-DD as a substrate for uPA were further explored by incubating either LMWuPA or HMWuPA with PDGF-DD(fl). Both forms of uPA generated two distinct PDGF-DD species (Figure 3a) , and even after four hours, when the system was almost depleted of PDGF-DD(fl), the cleavage remained limited and specific. Activity of the generated PDGF-DD species was confirmed in a tyrosine phosphorylation assay where the cleavage products were shown to induce PDGFRb activation (Figure 3b) . Moreover, addition of soluble uPAR did not affect HMWuPA-mediated cleavage, whereas cell-bound uPAR increased PDGF-DD activation by transfected uPA (Figure 3c ). These observations suggested that scuPA alone is not able to activate PDGF-DD(fl), whereas the presence of uPAR can enhance its catalytic efficacy by facilitating its conversion to HMWu-PA (arrowheads, Figure 3c ) and possibly also by altering the limited activity retained within scuPA. Further studies are needed to sort out what additional operative factors that might be involved in this process, but plasmin does not seem to be a requirement for this activation to take place as a2-antiplasmin was included in the assay. Based on these findings, it is reasonable to assume that uPAR-bound uPA binds and activates PDGF-DD near the cell surface. In complement to the above experiment, the generated PDGF-DD species were analysed for their ability to induce PDGFRb tyrosine phosphorylation. Serum-free conditioned media from cells transfected with constructs encoding the different mutant PDGF-D(fl) species were incubated with HMWu-PA and thereafter applied on PDGFRb-expressing PAE cells. Following cell lysis and specific immunoprecipitation of PDGFRb, the levels of tyrosine phosphorylation were determined by immunoblotting under reducing conditions. PDGFRb is regulated by uPAR and facilitates HMWuPA-induced PAE cell migration To explore the impact of uPA/uPAR on PDGF-DD/ PDGFRb signalling, stably transfected PAE cells expressing PDGFRb and/or uPAR were generated. Endogenous uPAR expression was essentially absent in the parental cells, whereas transfected cells expressed high levels of uPAR (Figure 4a ). The analysis also demonstrated that the forced overexpression of uPAR was accompanied by reduced amounts of PDGFRb. This inverse correlation was also noticed on the level of PDGFRb tyrosine phosphorylation, where decreased phosphorylation was detected in cells with high uPAR expression stimulated with PDGF-DD(GFD) (Figure 4b ). This effect was not ligand specific, as altered phosphorylation was also seen in PDGFRb/uPARexpressing cells stimulated with PDGF-BB. Furthermore, a dose-dependent response in these cells was observed upon increased addition of ligand, confirming Specific domain-domain interactions between PDGF-DD and uPA were identified by an ELISA. Serum-free conditioned media from transfected cells expressing the three depicted PDGF-DD species were applied to an ELISA plate coated with HMWuPA and LMWuPA, respectively. Bound PDGF-DD was assayed with specific polyclonal antibodies and visualized using the alkaline phosphatase yellow liquid substrate system. Data are presented as means of triplicates ± s.d. after subtraction of absorbance generated by coating proteins and serum-free medium. The PDGF-DD species generated by uPA-mediated proteolysis were analysed for their ability to induce PDGFRb tyrosine phosphorylation. Serum-free conditioned media from cells transfected with PDGF-D(fl) were incubated with LMWuPA or HMWuPA with or without the addition of soluble uPAR (suPAR) and thereafter applied on PDGFRb-expressing PAE cells. Following specific immunoprecipitation of PDGFRb, the levels of tyrosine phosphorylation were analysed by immunoblotting under reducing conditions. (c) The ability of scuPA to process PDGF-DD(fl) into active species was explored by applying serum-free conditioned media from cells transfected with PDGF-D(fl) and/or uPA as well as uPAR on PDGFRb-expressing PAE cells. Following cell lysis and specific immunoprecipitation of PDGFRb, the levels of tyrosine phosphorylation were analysed by immunoblotting under reducing conditions. To diminish undesired effects generated by plasmin activity induced by the presence of uPA, a2-antiplasmin was included in the serum-free cell culture media after transfection. Also protein levels of uPAR, uPA and PDGF-D(fl) in cells used as transfection host were monitored by immunoblotting under reduced conditions to control transfection efficacy and endogenous levels of protein of interest. Arrowheads indicate the presence of HMWuPA.
that saturation of receptor activity was not induced by the concentration used in the experimental setting (data not shown).
The stably transfected cell lines were further compared in a chemotaxis assay, where migratory properties in response to PDGF-DD(GFD) and HMWuPA were analysed. In comparison to cells expressing PDGFRb alone, PDGFRb/uPAR-expressing cells showed a decreased response to PDGF-DD(GFD) treatment ( Figure 4c ). This effect is likely a result of the altered expression levels and/or the decreased phosphorylation of PDGFRb in these cells. Cells transfected with uPAR alone responded weakly to HMWuPA, whereas coexpression with PDGFRb significantly increased the response, indicating that PDGFRb can act as a coreceptor for uPA/uPAR-induced PAE cell migration ( Figure 4d ). In summary, these results showed that both PDGFRb levels as well as activity could be regulated in a uPAR-dependent manner.
Activated PDGF-DD induces transformation of NIH/3T3 cells more effectively than latent PDGF-DD To investigate how proteolytic removal of the CUB domains from PDGF-DD(fl) affects tumorigenesis, NIH/3T3 cells with stable expression of PDGF-DD(GFD) were generated and compared with cells stably transfected with PDGF-D(fl) (Li et al., 2003) . Expression was confirmed by RT-PCR using primers specific for the PDGF-D(GFD) (Figure 5a ) and similar PDGF-D transcript levels were ensured by qRT-PCR using the same set of primers (data not shown). The majority of the transfected cells displayed transformed profiles, characterized by a small and round appearance. In addition, the cells expressing PDGF-DD(GFD) were shown to have an increased proliferative potential, as compared with cells expressing PDGF-DD(fl) in the absence of serum (Figure 5b ). These findings were consistent with that PDGF-D(CUB) spatially restricts the full activity of the growth factor. Equal growth rates were detected in the presence of serum (data not shown).
An important attribute of transformed cells is their anchorage-independent growth capacity. Therefore, the stably transfected cells were further investigated in a soft agar colony formation assay. In contrast to the control, cells expressing either form of PDGF-DD formed foci and the highest induction was detected in cells expressing the PDGF-DD(GFD) (Figure 5c ). Interestingly, not only the number of foci differed, but also the morphology. Smaller and more unevenly shaped foci formed from PDGF-DD(GFD) expressing cells, compared with cells expressing PDGF-DD(fl). Finally, to PAEuPAR PAE /uPAR migration index 220 P A E P A E P A E u P A R P A E u P A R P A E u P A R P A E u P A R P A E u P A R P A E u P A R P A E u P A R confirm that proteolytic activation is a critical determinant for PDGF-DD activity, a processing-resistant mutant, PDGF-D(fl) AAAA , was included in the experiment. As expected, the inability to release the GFD also prevented anchorage-independent growth (data not shown).
Given that the activated form of PDGF-DD induced transformation more effectively than the latent form, we confirmed that the proteolytic activation is rate limiting. Therefore, the endogenous expression of uPA and uPAR was next analysed by immunostaining (Figure 5d ). Cells expressing PDGF-DD(fl), as well as cells expressing PDGF-DD(GFD), clearly upregulated uPA compared with control cells. The expression levels of uPAR were overall high and did not seem to correlate with transformation. We concluded that uPA acts as a marker of cellular transformation and also likely facilitates activation of secreted PDGF-DD(fl) in an autocrine fashion.
Latent PDGF-DD induces tumour growth in nude mice more effectively than activated PDGF-DD The transformed NIH/3T3 cells with stable overexpression of PDGF-DD(fl) and PDGF-DD(GFD), were further analysed for their ability to induce tumour formation in nude mice. Surprisingly, despite the more efficient transformation capacity of the PDGF-DD(GFD) in vitro, tumours derived from these cells grew significantly slower in vivo (Figure 6a ). An analysis of vessel number by PECAM-1/CD31 immunostaining ( Figure 6b ) further showed that the total number of vessels remained the same between the two groups, but larger vessels were more abundant in tumours derived from cells expressing PDGF-DD(fl).
The presence of PDGF-DD, uPA and uPAR in excised tumours was considered by immunostaining. We argued that in vivo, the activation of PDGF-DD(fl) might no longer be rate limiting in the same way as noted in vitro, as long as an activating protease is present. The high abundance of uPA, mainly confined to a subset of tumour cells and some stromal fibroblast-like cells, supported this hypothesis (Figure 6c ). Also uPAR, expected to localise and enhance uPA activity, was present in both tumour types and located to vessel walls as well as surrounding tumour cells, particularly in the hypoxic region close to necrotic areas (data not shown). The high expression of uPA and uPAR indicated that PDGF-DD(fl) could be effectively activated in the local milieu.
The pericellular localization of PDGF-DD is controlled by proteolytic processing Potential mechanisms underlying the detected difference in tumour growth rates were addressed according to the view that latent and activated PDGF-DD might display different spatial distribution. In line with this hypothesis, immunostaining of non-permeabilized NIH/3T3 fibroblasts transiently transfected with PDGF-D(fl) and PDGF-D(GFD), respectively, revealed deposition of the GFD within near association of the producing cell, whereas secreted PDGF-DD(fl) displayed only minor pericellular retention (Figure 7a ). Comparable findings were also seen in transfected HEK293, CHO and COS-1 cells (data not shown). The well-characterized splice isoforms of VEGF-B (Olofsson et al., 1996) were used to show stainings of known diffusible versus matrix-bound growth factors. As expected, matrix-bound VEGF-B 167 induced strong pericellular staining after secretion, whereas the freely diffusible VEGF-B 186 did not (Figure 7b ).
Discussion
In this study, we elucidated how PDGF-DD activity can be regulated by the uPA/uPAR system (Figure 8 ), which in turn is known to be associated with human cancer progression. We demonstrated that both HMWuPA and LMWuPA could process PDGF-DD into active species and that the amino terminal fragment of uPA was not required for the interaction; the short A-chain disulphide-linked to the protease domain of uPA was sufficient. Interaction sites within PDGF-DD were identified to be predominantly located to the GFD. A likely scenario is though, that the CUB domain can modify the interaction with uPA by an as of yet unknown mechanism, especially since we have previously shown that the structurally related CUB domains in PDGF-CC have the ability to interact with tPA. Structural determinants required for PDGF-DD activation were further explored by dissecting the importance of the putative cleavage site region. Recently, the introduction of a double mutation (R247A, R249A) in PDGF-D was shown to effectively reduce uPA-mediated activation of PDGF-DD (Ustach and Kim, 2005) and our data more specifically demonstrated that R249A alone is responsible for this reported phenomenon. However, as tPA-induced activation of PDGF-CC is confined to a conserved tribasic site, it is likely that uPA has preferences for a similar site in PDGF-DD. Our analysis also demonstrated that the conserved tribasic -R 254 KSK-site in PDGF-DD was required for effective activation, even though the actual processing by uPA is likely confined to -R 249 . This is further supported by a previous report suggesting a preference for glycine at the P2 subsite of tPA and uPA substrates (Ke et al., 1997) . Owing to its small size, glycine is expected to render the basic cleavage site more exposed to activating proteases and accordingly, this may also explain why removal of the bulky arginine side chain in the R247A mutation enhanced PDGF-DD activation. Based on these findings, it is tempting to speculate about the possibility to modulate PDGF-DD activation by rendering the conserved basic stretch of residues more or less exposed to the activating protease, for instance by specific site-directed antibodies. The role of uPAR in PDGF-DD biology is largely unknown. We have addressed the possibility that cell surface bound complexes of uPA/uPAR regulate activation of PDGF-DD, partly as a result of a locally increased uPA concentration, but also by the prolonged and directed proteolytic activity of uPAR-bound uPA. Consistent with reports showing a prognostic value of uPA and uPAR in suggested PDGF-DD/PDGFRb driven pathologies such as prostate cancer (Miyake et al., 1999; Ustach and Kim, 2005) , this proposed mechanism is likely to be beneficial for regulating the efficacy of PDGF-DD activation in the local milieu. Our results confirmed that the presence of uPAR increased PDGF-DD activation by uPA under certain conditions, but also showed that uPAR was not an absolute requirement for the activation to occur. The in vivo role of uPA/uPAR in PDGF-DD regulated activation remains to be elucidated, although our tumour xenograft model pointed to a possible role for uPA and uPAR in PDGF-DD driven malignancies.
The high level of complexity that can be ascribed to uPA activity is reflected by the recent identification of PDGF-DD as a substrate. On one hand, uPA regulates PDGF-DD signalling; on the other hand, uPA may act as a direct ligand itself through uPAR-PDGFRb complex formation (Kiyan et al., 2005) . Indeed, we show that high uPAR expression induces decreased PDGFRb signalling mediated by PDGF-DD(GFD), but also that the presence of PDGFRb increases HMWuPA-mediated signalling. The exact mechanism and the overall significance of this must be evaluated in other systems both in vitro and in vivo, especially as the conclusions traditionally derived from uPA signalling studies may instead reflect responses originating from activation of endogenously derived latent PDGF-DD.
In addition to previous reports demonstrating an oncogenic potential of PDGF-DD (LaRochelle et al., 2002; Li et al., 2003; Xu et al., 2005) , the current work shows that a regulated PDGF-DD activation is beneficial for driving tumour growth. This finding was initially unexpected, as the PDGF-DD(GFD) more potently transformed NIH/3T3 cells in vitro. However, considering that altered pericellular retention and/or matrix interactions are important determinants for the physiological action of many other growth factors (LaRochelle et al., 1991; Ostman et al., 1991; Carmeliet et al., 1999; Grunstein et al., 2000; Lindblom et al., 2003; Lee et al., 2005) , this could be a likely mechanism for controlling the function of PDGF-DD as well. In line with this, one could speculate that the observed differences in foci morphology induced by the two PDGF-DD forms are due to different spatial distribution, especially as we have previously shown that smaller and unevenly shaped foci can be formed from NIH/3T3 cells overexpressing matrix-bound PDGF-BB (Li et al., 2003) . Indeed, here we show that latent PDGF-DD is diffusible, whereas the activated counterpart is deposited in close association with the producer cell, despite the lack of recognizable C-terminal retention motifs in the primary structure. Thus, the CUB domains in PDGF-DD(fl) do not appear to function as a link between PDGF-DD and the extracellular matrix. Instead, removal of the CUB domains exposes otherwise cryptic interacting sites causing the GFD to become pericellularly deposited. This would mean that the nontethered form can stimulate growth of both tumour and stromal cells locally and at some distance, thus supporting tumour growth better than the pericellularly retained form, which presumably acts more locally. Moreover, the producing sites of the processing enzyme, rather than the sites of synthesis of PDGF-DD(fl), may dictate the biological outcome. In conclusion, the concept that uPA can regulate both the activity, as well as the retention properties of PDGF-DD, provides valuable information about fundamental principles affecting PDGF-DD bioavailability.
Materials and methods
Cell culture, transfection and immunoblotting Cells were cultured under standard conditions as described (Fredriksson et al., 2005) . Wild-type and human PDGFRbexpressing PAE cell lines were stably transfected with a human uPAR expression vector using Lipofectamine LTX Reagent (Invitrogen, Stockholm, Sweden) and after clonal selection and expansion, maintained in a medium containing 250 mg/ml Zeocin. High expression levels of uPAR were confirmed by immunoblotting using a goat anti-human uPAR antibody (AF807, RnD Systems, Abingdon, UK). Transfections of other cell lines used were performed as described (Li et al., 2003; Fredriksson et al., 2005) . Proteins subjected for immunoblotting were separated by SDS-PAGE under reducing conditions, incubated with specific primary antibodies and visualized by appropriate, HRP-linked, secondary antibodies: donkey anti-goat IgG (sc2020, Santa Cruz Biotechnology, CA, USA), donkey anti-rabbit IgG (NA934V, Amersham Biosciences, Uppsala, Sweden) or sheep anti-mouse IgG (NXA931, Amersham Biosciences). Chemiluminescence plus reagent (Amersham Biosciences) was used for signal amplification.
Cloning and plasmid construction All primers (listed in Table 1 ) were purchased from Invitrogen and generated constructs were verified by nucleotide sequencing. Human PDGF-D(fl) (Bergsten et al., 2001 ) was used as a template for the PDGF-D cleavage site mutants and point mutations were introduced by PCR using Phusion DNA Based on previous reports, uPA has independent of its catalytic activity been suggested to induce intracellular signalling, partly through uPAR-mediated interactions with other cell surface receptors and transmembrane proteins, but more important for this study, also through transient colocalization of PDGFRb and uPAR in vascular smooth muscle cells. Our present study extends these findings and points to a functional role for the interaction between uPAR and PDGFRb for downstream signalling events. We demonstrate that PDGFRb protein levels can be negatively regulated by the presence of uPAR, whereas uPA-induced signalling is increased by the presence of PDGFRb. A S/L , A-chain short/long ; B, B-chain.
Polymerase (Finnzymes) under standard conditions. The primers were designed to enable PCR amplification of the entire vector construct. Using mouse PDGF-D(fl) (Li et al., 2003) as template, a processing-resistant mutant was generated by replacing the conserved-R 254 KSK-site with four alanines. The N-and C terminus were separately amplified by PCR using Taq DNA polymerase (Invitrogen). The same template was further used for amplification of the nucleotide sequence encoding the PDGF-D(GFD). The product was first cloned in-frame with the Igk-chain leader sequence of a modified pSecTag2A vector (Invitrogen) and then, accompanied by the leader sequence, subcloned into the final expression vector.
Both human uPA and human uPAR cDNA clones were obtained from the fibroblastic cell line AG1523 using standard cloning conditions as described (Fredriksson et al., 2004) .
Characterization of the PDGF-DD cleavage site Serum-free conditioned media from COS-1 cells, transfected with the various PDGF-D(fl) constructs, were incubated with 10 mg/ml HMWuPA (128, American Diagnostica Inc., CT, USA) for 2 h at RT. Thereafter, proteins were either precipitated with trichloroacetic acid directly, or first applied on serum-starved PAEb cells stably expressing PDGFRb, to analyse receptor activation as described (Fredriksson et al., 2005) . Precipitated proteins were detected by immunoblotting using a polyclonal goat anti-human PDGF-DD antibody (AF1159, RnD Systems). The membrane was subsequently stripped and reprobed with a rabbit anti-mouse uPA antiserum (IASMUPA, Innovative Research Inc., MI, USA) for detection of uPA.
Protein-protein interaction studies
His 6 -tagged PDGF-DD(fl) protein, expressed in serum-free medium (Bergsten et al., 2001) , was bound to nickelnitrilotriacetic acid (Ni-NTA)-agarose (Qiagen, Hilden, Germany) and incubated with serum-free conditioned media from scuPA-transfected COS-1 cells as described (Fredriksson et al., 2005) . Eluted proteins were analysed by immunoblotting using goat anti-human uPA IgG (398, American Diagnostica Inc.). The membrane was subsequently stripped and reprobed with a monoclonal mouse anti-his antibody (R930-25, Invitrogen) to detect PDGF-D. Specific domain-domain interactions between PDGF-DD and uPA were identified in an ELISA assay. A 96-well EIA/RIA plate (Corning Inc., Schiphol-Rijk, The Netherlands) was coated overnight with 50 mg/ml HMWuPA and equimolar amounts of LMWuPA (IUPA-LMW, Innovative Research Inc.). Thereafter, serum-free conditioned media from COS-1 cells transfected with the three different PDGF-D constructs, were applied to the plate and protein interactions were allowed for 90 min. After washing with PBS, bound PDGF-DD species were recognized by an affinity-purified polyclonal rabbit anti-human PDGF-DD antibody and secondary goat anti-rabbit IgG (whole molecule)-alkaline phosphatase (A8025, Sigma-Aldrich, Stockholm, Sweden). Absorbance was read at 405 nm after incubation with alkaline phosphatase yellow (pNPP) liquid substrate system for ELISA (Sigma-Aldrich). The specificity of the primary antibody against PDGF-DD(CUB) and PDGF-DD(GFD), was confirmed by immunofluorescence (data not shown).
Processing and activation of PDGF-DD
The proteolytic activation of PDGF-DD(fl) by uPA was explored by incubating 2.5 mg purified PDGF-DD ( Bergsten et al., 2001) in PBS with either 0.5 mg LMWuPA or 2.5 mg HMWuPA for 2 and 4 h, respectively, at RT. Comparable enzymatic activities were determined beforehand, by a Spectrozyme uPA assay (American Diagnostica Inc.) (data not shown). Immunoblotting of generated PDGF-D species, as well as uPA, was carried out as above. The activation of PDGF-DD(fl) was further studied by transfecting COS-1 cells with PDGF-D(fl), scuPA and uPAR. To eliminate possible plasmin remnants, a2-antiplasmin (American Diagnostica Inc.) was added, where stated, to a final concentration of 30 nM to the serum-free media. Conditioned media were collected and incubated as illustrated using 1.6 mg/ml LMWu-PA or 8 mg/ml HMWuPA with or without the addition of 12 mg/ml soluble uPAR (807-UK, RnD Systems). PDGF-DD activity was assayed by PDGFRb tyrosine phosphorylation as above.
Analysis of PAE cells expressing PDGFRb and uPAR
For visualization of uPAR and PDGFRb expression, PAE cells were lysed on ice (Fredriksson et al., 2005) , collected and centrifuged. The lysates were thereafter analysed by immunoblotting using a goat polyclonal anti-human uPAR antibody (AF807, RnD Systems) and a rabbit monoclonal antibody against human PDGFRb (3169, Cell Signaling Technology, MA, USA). Loading of equal amounts of total protein was confirmed by a polyclonal goat anti-human calnexin antibody (sc-6465, Santa Cruz Biotechnology). Cells expressing PDGFRb, with or without co-expression of uPAR were stimulated with 200 ng/ml PDGF-DD(GFD), 80 ng/ml PDGF-BB or 150 ng/ml HMWuPA. PDGFRb tyrosine phosphorylation was detected as above.
Functional PDGFRb activity was studied in a chemotaxis assay using cell culture inserts (BD Biosciences, Erembodegen, Belgium), where migration through translucent 8 mm pore size membranes was induced by addition of exogenous ligands in the lower compartment. PAE cell lines were initially starved overnight in serum-free medium supplemented with 0.5% BSA and thereafter seeded, 40 000 cells/insert, allowed to attach and treated for 4 h with 300 ng/ml PDGF-DD(GFD) and 80 ng/ml HMWuPA, respectively. Non-migrating cells on the upper side were removed with cotton swabs before membranes were briefly air-dried and mounted using Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories, CA, USA), thereby visualizing nuclei of cells attached to the lower side of the membrane. Average number of migrated cells were analysed from three independent experiments with eight representative views/membrane using a Â 10 objective and the AxioVision Rel. 4.6 Software (Carl Zeiss) and normalized to untreated control cells.
Characterization of stably transfected NIH/3T3 cells After transfection and selection, NIH/3T3 cells were screened for PDGF-DD expression, both on protein (data not shown) and mRNA level (Figure 5a ) using mb2-microglobulin as an endogenous reference gene. Primers used for RT-PCR analysis were 5 0 -tgaagctgaccaatgcagtc (forward, mPDGF-D(GFD)), 5 0 -ttgccccttctcttgaaatg (reverse, mPDGF-D(GFD)), 5 0 -ctgaccggcctgtatgctat (forward, mb2-microglobulin) and 5 0 -ccgttcttcagcatttggat (reverse, mb2-microglobulin).
To monitor cell growth, cells were seeded in 12-well plates at a density of 1 Â 10 4 cells per well and thereafter counted everyday for 5 days using a Coulter counter.
Anchorage-independent growth was assessed by analysing foci formation in low melting agarose/DMEM as described (Li et al., 2003) .
Analysis of endogenous uPA and uPAR expression in stably PDGF-D transfected NIH/3T3 cells was performed by immunofluorescent staining. Cells were prepared as described (Li et al., 2003) and proteins of interest recognized by a rabbit anti-mouse uPA antiserum and a polyclonal goat anti-mouse uPAR antibody (AF534, RnD Systems) in permeabilized cells. Alexa Fluor 594 donkey anti-rabbit IgG (A21207, Invitrogen) and Alexa Fluor 488 donkey anti-goat IgG (A11055, Invitrogen), respectively, were used for visualization. All nuclei were stained with 4 0 ,6-diamidine-2 0 -phenylindoledihydrochloride (DAPI, Roche Applied Science, Mannheim, Germany).
NIH/3T3 tumour studies in nude mice
The in vivo tumorigenicity of NIH/3T3 cells stably expressing PDGF-DD(fl) or PDGF-DD(GFD) was investigated in 8-week-old female Balb/C nude mice. Exponentially growing cells (1 Â 10 6 ) were implanted subcutaneously in the midline dorsum of each mouse. Tumour volume was monitored and calculated using the formula: width 2 Â length Â 0.52 (Boehm et al., 1997) and when any of the tumours reached 1000 mm 3 , all tumours were excised and fixated in 4% paraformaldehyde. Animal experiments were approved by the local committee for animal experiments and performed according to United Kingdom Coordinating Committee on Cancer Research guidelines (1998).
Immunohistochemical stainings were carried out on tissue sections from paraffin-embedded xenografts. A monoclonal rat anti-mouse PECAM-1/CD31 antibody (550274, BD Biosciences) was used for detection of blood vessels, after exposing the sections to 0.05% Trypsin/EDTA (Invitrogen). The chromogenic signal was amplified with TSA INDIRECT (PerkinElmer Life and Analytical Sciences). PDGF-DD expression was visualized with an affinity-purified polyclonal rabbit anti-human PDGF-DD antibody, uPA expression with the rabbit anti-mouse uPA antiserum and uPAR expression with the polyclonal goat anti-mouse uPAR antibody. Elite ABC Vectastain (Vector Laboratories) was used for signal development. Appropriate secondary antibodies were from the signal amplification kits or bought separately (Vector Laboratories).
Immunofluorescent stainings of transiently transfected NIH/3T3 cells NIH/3T3 cells were transfected with PDGF-D(fl) and PDGF-D(GFD), and prepared as described (Li et al., 2003) . PDGF-DD deposition was analysed using a polyclonal rabbit antihuman c-myc antibody (sc-789, Santa Cruz Biotechnology) and visualized by an Alexa Fluor 488 goat anti-rabbit IgG antibody (A11008, Invitrogen). Human VEGF-B 186 and VEGF-B 167 deposition was similarly analysed using a monoclonal mouse anti-human VEGF-B antibody (MAB3372, RnD Systems) and visualized by an Alexa Fluor 488 donkey antimouse IgG antibody (A21202, Invitrogen).
